For example, the NICE appraisal of lapatinib or trastuzumab in combination with an aromatase inhibitor (AI) is recommended as the first-line treatment of HER2-positive advanced breast cancer (ABC), in the hormone-receptor-positive (HR+ve) population only (TA257; https://www.nice.org.uk/guidance/ta257). The gene discussed is NR4A1; the disease is breast carcinoma.